# Safety and Efficacy of Radio-immunotherapy (RIT) for Patients With Relapse or Refractory Acute Lymphoblastic Leukaemia (ALL) B CD22+

> **NCT01354457** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Nantes University Hospital** · enrollment: 21 (estimated)

## Conditions studied

- Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Epratuzumab and 90Y-Epratuzumab

## Key facts

- **NCT ID:** NCT01354457
- **Lead sponsor:** Nantes University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-11
- **Primary completion:** 2016-06
- **Final completion:** 2016-06
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2014-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01354457

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01354457, "Safety and Efficacy of Radio-immunotherapy (RIT) for Patients With Relapse or Refractory Acute Lymphoblastic Leukaemia (ALL) B CD22+". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT01354457. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*